Additionally, studies have demonstrated the clinical relevance of Tks5 expression in cancer, such as glial-derived brain tumors, lung adenocarcinomas, prostate cancer and breast cancer [21, 38–40]. The gene discussed is SH3PXD2A; the disease is prostate carcinoma.